A Preliminary Study About Unexplained Recurrent Miscarriage and Repeated Implantation Failure Patients Treated With Low-dose Lymphocyte Immunotherapy (immunotherapy)
Primary Purpose
Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
low-dose lymphocyte immunotherapy
Sponsored by
About this trial
This is an interventional treatment trial for Unexplained Recurrent Miscarriage and Recurrent Implantation Failure focused on measuring uRM, RIF, Th1, Th2, Treg, lymphocyte immunotherapy
Eligibility Criteria
Inclusion Criteria:
- Healthy except for their history of recurrent abortions and were negative for blocking antibodies
- Willing to receive follow up
Exclusion Criteria:
- Patients with genetic impairment
- Patients with Mullerian anomaly
- Patients with hormonal deficiency
- Patients with metabolic disorder
- Patients with infectious disease
- Patients with autoimmune abnormalities
Sites / Locations
- Reproductive Medicine Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
lymphocyte immunotherapy on uRM and RIF
Arm Description
Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
Outcomes
Primary Outcome Measures
T cell proportion
We use flow cytometry to detecte peripheral blood Th1、Th2 and Treg cells of uRM and RIF patients before and after low-dose lymphocyte immunotherapy to see if the immunotherapy have treatment effect on Th1/Th2/Treg paradigm disorder
Abortion rate
We undergo follow-up of all the uRM patients to see the abortion rate (miscarriage was confirmed by ultrasound before the 20th week of gestation) after lymphocyte immunotherapy
IVF outcomes
We observed the the implantation rate, clinical pregnancy rate, and ongoing pregnancy rate of RIF patients after low-dose lymphocyte immunotherapy
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03081325
Brief Title
A Preliminary Study About Unexplained Recurrent Miscarriage and Repeated Implantation Failure Patients Treated With Low-dose Lymphocyte Immunotherapy
Acronym
immunotherapy
Official Title
A Preliminary Study About Unexplained Recurrent Miscarriage and Repeated Implantation Failure Patients Treated With Low-dose Lymphocyte Immunotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
March 2015 (undefined)
Primary Completion Date
June 2017 (Actual)
Study Completion Date
July 20, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nanjing University
4. Oversight
5. Study Description
Brief Summary
Recurrent miscarriage(RM) and recurrent implantation failure (RIF) are clinical challenge for clinicians and patients who are desperate for a healthy child.The specific etiology contains chromosomal abnormalities, reproductive anatomical abnormalities, endocrine disorders, reproductive system infections, autoimmune and environmental factors. However there are still 50% to 60% RM and RIF which don't have a clear cause,mainly associated with alloimmune factors.Among various treatments,lymphocytes active immunotherapy is the most common treatment method, and its clinical efficacy is widely recognized although its action mechanism is not clear so far.
Detailed Description
The main mechanism of active immunotherapy includes upregulating Th2-type cytokines, downregulating Th1-type cytokines, making Th1 / Th2 shift to Th2, inducing maternal serum IL-6 and sIL6R, PIBF, EGF; inducing the expression of Fas / Fasl on lymphocyte surface; increasing the proportion of CD8 + cells, Th2-type cells and CD + CD25 + Treg cells, decreasing the activity of CD56 + CD16 + NK cell and so on.The purpose of this study is to observe the treatment effects of active immunotherapy on uRM and RIF patients. What's more,we will used flow cytometry, and quantitative real-time PCR (qPCR) methods to characterize Th1、Th2 and Treg cell populations after immunotherapy,ecpecting to find out the exact molecule mechanism of immunotherapy with paternal or third party lymphocytes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
Keywords
uRM, RIF, Th1, Th2, Treg, lymphocyte immunotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
292 (Actual)
8. Arms, Groups, and Interventions
Arm Title
lymphocyte immunotherapy on uRM and RIF
Arm Type
Experimental
Arm Description
Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
Intervention Type
Procedure
Intervention Name(s)
low-dose lymphocyte immunotherapy
Intervention Description
Peripheral venous blood (PBMCs) was drawn from the husbands of uRM and RIF patients and then the PBMCs were resuspended and administered intradermally to uRM and RIF patients 3 times at 3-week intervals. Once conceived, the uRM and RIF patients undergo 2 rounds of treatment at 8-week intervals.
Primary Outcome Measure Information:
Title
T cell proportion
Description
We use flow cytometry to detecte peripheral blood Th1、Th2 and Treg cells of uRM and RIF patients before and after low-dose lymphocyte immunotherapy to see if the immunotherapy have treatment effect on Th1/Th2/Treg paradigm disorder
Time Frame
1 year
Title
Abortion rate
Description
We undergo follow-up of all the uRM patients to see the abortion rate (miscarriage was confirmed by ultrasound before the 20th week of gestation) after lymphocyte immunotherapy
Time Frame
1 year
Title
IVF outcomes
Description
We observed the the implantation rate, clinical pregnancy rate, and ongoing pregnancy rate of RIF patients after low-dose lymphocyte immunotherapy
Time Frame
1 year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Healthy except for their history of recurrent abortions and were negative for blocking antibodies
Willing to receive follow up
Exclusion Criteria:
Patients with genetic impairment
Patients with Mullerian anomaly
Patients with hormonal deficiency
Patients with metabolic disorder
Patients with infectious disease
Patients with autoimmune abnormalities
Facility Information:
Facility Name
Reproductive Medicine Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
29246150
Citation
Liu M, Zhen X, Song H, Chen J, Sun X, Li X, Zhou J, Yan G, Ding L, Sun H. Low-dose lymphocyte immunotherapy rebalances the peripheral blood Th1/Th2/Treg paradigm in patients with unexplained recurrent miscarriage. Reprod Biol Endocrinol. 2017 Dec 16;15(1):95. doi: 10.1186/s12958-017-0315-9.
Results Reference
derived
Learn more about this trial
A Preliminary Study About Unexplained Recurrent Miscarriage and Repeated Implantation Failure Patients Treated With Low-dose Lymphocyte Immunotherapy
We'll reach out to this number within 24 hrs